AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20196388 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine for 9 months for Classes IV and V patients
Number of subjects: 18
Study 20196388 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme (ACE) inhibitors for all patients
Number of subjects: 18
Study 20196388 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment protocol for severe HSP nephritis
Number of subjects: 18
Study 17454701 — intervention group
Group type: EXPERIMENTAL
Intervention: Active drug (nortriptyline hydrochloride)
Number of subjects: 345
Study 17454701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 345
Study 15196296 — intervention group
Group type: EXPERIMENTAL
Intervention: rizatriptan 10 mg
Number of subjects: 1447
Study 15196296 — intervention group
Group type: EXPERIMENTAL
Intervention: rizatriptan 5 mg
Number of subjects: 1447
Study 15196296 — intervention group
Group type: EXPERIMENTAL
Intervention: rizatriptan 10 mg and 5 mg
Number of subjects: 1447
Study 12189544 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultants' communication behaviours with women affected by breast cancer
Number of subjects: 158
Study 12189544 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultants' communication behaviours with unaffected women
Number of subjects: 158
Study 12189544 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultants' communication behaviours with younger women
Number of subjects: 158
Study 12189544 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultants' communication behaviours with women with medical and allied health training
Number of subjects: 158
Study 12189544 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultants' communication behaviours with women in non-professional occupations
Number of subjects: 158
Study 12189544 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultants' communication behaviours with women with a family history of breast and ovarian cancer
Number of subjects: 158
Study 12189544 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultants' communication behaviours with affected women
Number of subjects: 158
Study 9694753 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B in glucose 5%
Number of subjects: 51
Study 9694753 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B in intralipid 20%
Number of subjects: 51
Study 8088068 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA) starting dose 5 mg/kg
Number of subjects: 117
Study 8088068 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA) starting dose 1.5-2 mg/kg
Number of subjects: 117
Study 2760256 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (mean daily dose 360 mg)
Number of subjects: 23
Study 2760256 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (mean daily dose 90 mg)
Number of subjects: 23
Study 2760256 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination diltiazem-nifedipine therapy (mean daily dose 55 mg of nifedipine, 360 mg of diltiazem)
Number of subjects: 23
Study 2760256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 790555 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen (200 mg daily)
Number of subjects: 30
Study 790555 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (3.6 g daily)
Number of subjects: 30
Study 31207178 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin/Metformin FDC tablet (2.5 mg/500 mg, 7.5 mg/850 mg, or 7.5 mg/1000 mg)
Number of subjects: 34
Study 31207178 — intervention group
Group type: COMPARATOR
Intervention: Coadministration of individual components (ertugliflozin with metformin)
Number of subjects: 34
Study 29713647 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP)
Number of subjects: 37
Study 29713647 — intervention group
Group type: COMPARATOR
Intervention: Sterile 0.9% saline (Control)
Number of subjects: 37
Study 26577940 — intervention group
Group type: EXPERIMENTAL
Intervention: FAZA PET imaging
Number of subjects: 41
Study 26577940 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin treatment in PET-hypoxic tumors
Number of subjects: 41
Study 26577940 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirapazamine treatment in PET-hypoxic tumors
Number of subjects: 41
Study 26577940 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG PET imaging
Number of subjects: 41
Study 25115911 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Emission Zones (LEZs)
Number of subjects: 3000000
Study 22205034 — intervention group
Group type: EXPERIMENTAL
Intervention: Dequalinium chloride (DQC) vaginal tablets
Number of subjects: 321
Study 19681784 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin
Number of subjects: 36
Study 19681784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 18412980 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pectin diet (enteral formula: pectin liquid = 2:1)
Number of subjects: 18
Study 18412980 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pectin diet (enteral formula: pectin liquid = 3:1)
Number of subjects: 18
Study 16029627 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose IFN alpha-2b 5MIU 6 times per week for 3 - 6 months
Number of subjects: 30
Study 16029627 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose IFN alpha-2b 3MIU every other day for 3 - 6 months
Number of subjects: 30
Study 16029627 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 30
Study 12915606 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 4 mg
Number of subjects: 773
Study 12915606 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 8/4 mg
Number of subjects: 773
Study 12915606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 773
Study 10452405 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 1833
Study 8548191 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet
Number of subjects: 0
Study 8548191 — intervention group
Group type: COMPARATOR
Intervention: Ganciclovir
Number of subjects: 0
Study 8548191 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet and Ganciclovir
Number of subjects: 0
Study 1779539 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed transport of antibiotics in autologous blood shadows
Number of subjects: 73
Study 1779539 — intervention group
Group type: COMPARATOR
Intervention: Traditional nonoperative treatment
Number of subjects: 73
Study 7014570 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole/ASA
Number of subjects: 364
Study 7014570 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 364
Study 28398490 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy-Defibrillator (CRT-D)
Number of subjects: 1270
Study 28398490 — intervention group
Group type: COMPARATOR
Intervention: Implantable Cardioverter Defibrillator (ICD)
Number of subjects: 1270
Study 27593381 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injected (1.5 ml)
Number of subjects: 19
Study 27593381 — intervention group
Group type: COMPARATOR
Intervention: Normal saline injected (1.5 ml)
Number of subjects: 19
Study 25122597 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic steroid injection
Number of subjects: 31
Study 22645323 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid avoidance
Number of subjects: 222
Study 22645323 — intervention group
Group type: COMPARATOR
Intervention: Maintenance steroids
Number of subjects: 222
Study 20380718 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional Family Therapy (MDFT)
Number of subjects: 450
Study 20380718 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 450
Study 18940487 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 IA infiltration of sodium hyaluronate (1 mL)
Number of subjects: 41
Study 18940487 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of methocarbamol (380 mg) and paracetamol (300 mg) every 6 hours for 4 weeks
Number of subjects: 41
Study 17477204 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthesia instructions - 'think of the hand as numb and insensitive as if it were a piece of rubber...'.
Number of subjects: 80
Study 17477204 — intervention group
Group type: COMPARATOR
Intervention: Hypnotic induction procedure
Number of subjects: 80
Study 17477204 — intervention group
Group type: COMPARATOR
Intervention: Demands for honest reports
Number of subjects: 80
Study 12585146 — intervention group
Group type: EXPERIMENTAL
Intervention: Yufeng Capsule (YFC)
Number of subjects: 171
Study 12585146 — intervention group
Group type: COMPARATOR
Intervention: Venoruton (Control)
Number of subjects: 171
Study 11147151 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed kinetic chain (CKC) exercises
Number of subjects: 44
Study 11147151 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed kinetic chain (CKC) + open kinetic chain (OKC) exercises
Number of subjects: 44
Study 9174305 — intervention group
Group type: EXPERIMENTAL
Intervention: IT neostigmine 10, 30, or 100 microg
Number of subjects: 24
Study 9174305 — intervention group
Group type: COMPARATOR
Intervention: IT placebo (glucose control)
Number of subjects: 24
Study 1540431 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (5000 units intravenously followed by 1000 units hourly without dose adjustment)
Number of subjects: 652
Study 1540431 — intervention group
Group type: COMPARATOR
Intervention: Placebo for heparin
Number of subjects: 652
Study 1540431 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 652
Study 3536765 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 41740 (Biostim®) 8 mg daily for 14 days
Number of subjects: 0
Study 3536765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30273569 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump CABG
Number of subjects: 2203
Study 30273569 — intervention group
Group type: COMPARATOR
Intervention: Off-pump CABG
Number of subjects: 2203
Study 30273569 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump and Off-pump CABG
Number of subjects: 2203
Study 30264918 — intervention group
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Number of subjects: 0
Study 30264918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27783545 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to Patient Drug Adherence Information (PDAI)
Number of subjects: 219
Study 27783545 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to PDAI
Number of subjects: 219
Study 25900517 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC (FF 100 μg/LEVO 200 μg)
Number of subjects: 71
Study 25900517 — intervention group
Group type: EXPERIMENTAL
Intervention: FF (100 μg)
Number of subjects: 71
Study 25900517 — intervention group
Group type: EXPERIMENTAL
Intervention: LEVO (200 μg)
Number of subjects: 71
Study 25900517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 23084100 — intervention group
Group type: EXPERIMENTAL
Intervention: Grafted moderate lesions
Number of subjects: 619
Study 23084100 — intervention group
Group type: COMPARATOR
Intervention: Ungrafted moderate lesions
Number of subjects: 619
Study 23084100 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-sided grafts (arterial and vein)
Number of subjects: 619
Study 23084100 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-sided grafts
Number of subjects: 619
Study 23084100 — intervention group
Group type: COMPARATOR
Intervention: Moderate lesions in the right coronary artery (ungrafted)
Number of subjects: 619
Study 23084100 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate lesions in the left coronary territory (grafted)
Number of subjects: 619
Study 21042763 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 mg/m2 docetaxel
Number of subjects: 73
Study 21042763 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 mg/m2 irinotecan with 5-FU/leucovorin
Number of subjects: 73
Study 21042763 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal baseline tumour marker levels (except CA72-4)
Number of subjects: 73
Study 21042763 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline tumour marker levels
Number of subjects: 73
Study 21042763 — intervention group
Group type: EXPERIMENTAL
Intervention: Early changes in tumour markers during treatment
Number of subjects: 73
Study 21042763 — intervention group
Group type: EXPERIMENTAL
Intervention: Model combining baseline level, change, and interaction
Number of subjects: 73
Study 19213350 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention Enema (RE) group
Number of subjects: 93
Study 19213350 — intervention group
Group type: COMPARATOR
Intervention: Oral Medicated (OM) group
Number of subjects: 93
Study 16380568 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicide Risk Screen
Number of subjects: 1323
Study 16380568 — intervention group
Group type: EXPERIMENTAL
Intervention: Simpler, more specific screening instrument
Number of subjects: 1323
Study 14740952 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent live attenuated dengue virus vaccine candidates
Number of subjects: 59
Study 14740952 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent vaccines (second dose at 30 or 90 days)
Number of subjects: 59
Study 14740952 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetravalent vaccine (single dose)
Number of subjects: 59
Study 14740952 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetravalent vaccine (second dose at one month)
Number of subjects: 59
Study 14740952 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetravalent vaccine (third dose at four months)
Number of subjects: 59
Study 11167770 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin (2 ng/kg)
Number of subjects: 2
Study 11167770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 8825535 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (10 mg iv)
Number of subjects: 78
Study 8825535 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (1.25 mg iv)
Number of subjects: 78
Study 8825535 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg iv)
Number of subjects: 78
Study 1405290 — intervention group
Group type: EXPERIMENTAL
Intervention: Gidazepam
Number of subjects: 0
Study 1405290 — intervention group
Group type: COMPARATOR
Intervention: Ethacizin
Number of subjects: 0
Study 30958356 — intervention group
Group type: EXPERIMENTAL
Intervention: ω3‐FA supplementation (1.7g docosahexaenoic acid and 0.6g eicosapentaenoic acid daily for 6 months)
Number of subjects: 171
Study 30958356 — intervention group
Group type: EXPERIMENTAL
Intervention: ω3‐FA supplementation
Number of subjects: 171
Study 30958356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 27870826 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF‐1/rhIGFBP‐3, administered at 250 µg/kg/d continuous i.v. infusion up to postmenstrual age 29 wk+6 d
Number of subjects: 19
Study 27870826 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 19
Study 26346751 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐regulated training with exergames played with the Windows Kinect® sensor and FitBit® pedometer
Number of subjects: 0
Study 26346751 — intervention group
Group type: COMPARATOR
Intervention: Conventional self‐regulated exercise programs
Number of subjects: 0
Study 26346751 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (exergames and conventional exercises)
Number of subjects: 0
Study 23578197 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine
Number of subjects: 0
Study 23578197 — intervention group
Group type: EXPERIMENTAL
Intervention: Dealcoholized red wine
Number of subjects: 0
Study 23578197 — intervention group
Group type: EXPERIMENTAL
Intervention: Gin
Number of subjects: 0
Study 21329027 — intervention group
Group type: COMPARATOR
Intervention: Single Sling (SSling)
Number of subjects: 27
Study 21329027 — intervention group
Group type: COMPARATOR
Intervention: Double Sling (DSling)
Number of subjects: 27
Study 21329027 — intervention group
Group type: COMPARATOR
Intervention: Rescue Stretcher
Number of subjects: 27
Study 21329027 — intervention group
Group type: COMPARATOR
Intervention: Rescue Basket (RB)
Number of subjects: 27
Study 19895741 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligation group (19 patients)
Number of subjects: 39
Study 19895741 — intervention group
Group type: COMPARATOR
Intervention: Non-ligation group (20 patients)
Number of subjects: 39
Study 17635423 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-oxygenation followed by nasopharyngeal oxygen insufflation
Number of subjects: 34
Study 17635423 — intervention group
Group type: COMPARATOR
Intervention: Pre-oxygenation alone
Number of subjects: 34
Study 14766685 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonomyography
Number of subjects: 15
Study 14766685 — intervention group
Group type: COMPARATOR
Intervention: Balloon pressure mechanomyography
Number of subjects: 15
Study 12174060 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium tetradecyl sulfate sclerotherapy
Number of subjects: 20
Study 12174060 — intervention group
Group type: COMPARATOR
Intervention: Long-pulsed 1064 nm Nd:YAG laser irradiation
Number of subjects: 20
Study 9848295 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of luteal phase support in women with serum progesterone levels of > or = 60 ng/mL at 4 weeks' gestation
Number of subjects: 188
Study 9848295 — intervention group
Group type: COMPARATOR
Intervention: Continuation of luteal phase support in women with serum progesterone levels of < 60 ng/mL at 4 weeks' gestation
Number of subjects: 188
Study 7806870 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (18 patients)
Number of subjects: 40
Study 7806870 — intervention group
Group type: COMPARATOR
Intervention: Placebo (22 patients)
Number of subjects: 40
Study 2642453 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin + Cyclophosphamide + BCG (DC + BCG)
Number of subjects: 98
Study 2642453 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin + Cyclophosphamide + Cisplatin (DCP)
Number of subjects: 98
Study 2642453 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin + Cyclophosphamide + Cisplatin + BCG (DCP + BCG)
Number of subjects: 98
Study 241598 — intervention group
Group type: EXPERIMENTAL
Intervention: Alclofenac
Number of subjects: 35
Study 241598 — intervention group
Group type: COMPARATOR
Intervention: D-penicillamine
Number of subjects: 35
Study 30710664 — intervention group
Group type: EXPERIMENTAL
Intervention: tPEMF
Number of subjects: 20
Study 30710664 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study 26089332 — intervention group
Group type: EXPERIMENTAL
Intervention: Average SBP <144 mm Hg
Number of subjects: 541
Study 26089332 — intervention group
Group type: EXPERIMENTAL
Intervention: Average SBP >157 mm Hg
Number of subjects: 541
Study 26089332 — intervention group
Group type: COMPARATOR
Intervention: Average SBP between 144 and 157 mm Hg
Number of subjects: 541
Study 24725967 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood gene expression profiling
Number of subjects: 148
Study 21813090 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.59‐mg fluocinolone acetonide (FA) implant
Number of subjects: 196
Study 18692420 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour Graded Activity (BGA)
Number of subjects: 100
Study 18692420 — intervention group
Group type: COMPARATOR
Intervention: Conventional Exercise (CE)
Number of subjects: 100
Study 17717236 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine
Number of subjects: 222
Study 17717236 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine
Number of subjects: 222
Study 17717236 — intervention group
Group type: EXPERIMENTAL
Intervention: levobupivacaine
Number of subjects: 222
Study 15258869 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.075 mg/kg intravenous morphine sulfate
Number of subjects: 34
Study 15258869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 11705788 — intervention group
Group type: EXPERIMENTAL
Intervention: OCP (oral contraceptives containing progesterone)
Number of subjects: 8
Study 11705788 — intervention group
Group type: EXPERIMENTAL
Intervention: OCEP (oral contraceptives containing progesterone and estrogen)
Number of subjects: 8
Study 11705788 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular phase
Number of subjects: 8
Study 11705788 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase
Number of subjects: 8
Study 11705788 — intervention group
Group type: COMPARATOR
Intervention: OCP and OCEP
Number of subjects: 8
Study 9626922 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg once daily for 4 days
Number of subjects: 10
Study 9626922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9626922 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 10
Study 7829693 — intervention group
Group type: EXPERIMENTAL
Intervention: Ammonium chloride
Number of subjects: 26
Study 7829693 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Number of subjects: 26
Study 7829693 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral calcium (25 mmol)
Number of subjects: 26
Study 7829693 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic hypercalcaemia (primary hyperparathyroidism)
Number of subjects: 26
Study 7829693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 3050188 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime (CZX) 20 mg/kg intravenous dose
Number of subjects: 112
Study 3050188 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime (CZX) for prophylaxis
Number of subjects: 112
Study 3050188 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime (CZX) 10 mg/kg intravenous dose
Number of subjects: 112
Study 3050188 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime (CZX) 20 mg/kg one shot dose
Number of subjects: 112
Study 3050188 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime (CZX) in various dosing regimens
Number of subjects: 112
Study 3050188 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime (CZX)
Number of subjects: 112
Study 31782193 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal Spray (NS)
Number of subjects: 207
Study 31782193 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) kit
Number of subjects: 207